<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714530</url>
  </required_header>
  <id_info>
    <org_study_id>ThoRaT</org_study_id>
    <nct_id>NCT02714530</nct_id>
  </id_info>
  <brief_title>Thoracal Radiotherapy and Tarceva</brief_title>
  <acronym>ThoRaT</acronym>
  <official_title>Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if erlotinib given orally along with concurrent&#xD;
      palliative irradiation to lung cancer improves local control compared to those treated with&#xD;
      radiotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endpoints:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
        -  To determine if erlotinib given orally along with concurrent external beam radiation&#xD;
           therapy, prolongs local tumour control as determined by CT evaluation compared to&#xD;
           treatment with external beam radiation therapy alone&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To confirm the safety profile of erlotinib along with concurrent external beam radiation&#xD;
           therapy.&#xD;
&#xD;
        -  To evaluate if erlotinib along with concurrent external beam radiation therapy, improve&#xD;
           quality of life as assessed with the EORTC QLQ-C30 and the EORTC QLQ-LC13.&#xD;
&#xD;
        -  To evaluate if PET-CT examination can be used to predict response to treatment.&#xD;
&#xD;
        -  To evaluate overall survival in the different groups&#xD;
&#xD;
      Trial Design: Open multicenter two-armed randomized phase II trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with progression in radiation field among patients treated with erlotinib combined with radiotherapy compared to radiotherapy alone</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate local control by radiological evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events grade &gt;3 as Assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
    <description>To confirm the safety profile of erlotinib along with concurrent external beam radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival will be measured</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate overall survival in the different groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy 3 Gy x 10 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Tarceva daily during radiotherapy course</description>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_label>Radiotherapy combined with erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Histological or cytological verified NSCLC&#xD;
&#xD;
          -  Palliative radiotherapy to thorax indicated&#xD;
&#xD;
          -  ECOG Performance status 0-2&#xD;
&#xD;
          -  Fertile patients must use contraception&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Ability to understand and fill in QoL questionnaires&#xD;
&#xD;
          -  Capability to take per os medication&#xD;
&#xD;
          -  Serum bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2 times ULN (&lt; 5 times ULN if liver metastases are present)&#xD;
&#xD;
          -  Creatinine &lt; 5 times ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Other prior or concurrent malignant disease likely to interfere with study treatment&#xD;
             or comparisons&#xD;
&#xD;
          -  No evidence of other significant laboratory finding or concurrent uncontrolled medical&#xD;
             illness, that in the opinion of the investigator, would interfere with study treatment&#xD;
             or results comparison or render the patient at high risk for treatment complications&#xD;
&#xD;
          -  No prior radiotherapy to the same organ / place&#xD;
&#xD;
          -  No concurrent treatment with other experimental drugs&#xD;
&#xD;
          -  Known brain metastases in need of radiotherapy&#xD;
&#xD;
          -  Known hypersensitivity to erlotinib or other substances in the erlotinib tablets.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Åslaug Helland, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>International/Other</state>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7010</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Åslaug Helland</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publish results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

